Table 4.

Unadjusted associations between use of frontline therapy and rwOS

	Keynote 189	A	B	C	D	E
Number of patients	616	346/54	1,501/405	232/36	748/132	155/125
Number of events (Chemotherapy/ PD‐1 combination)	235	203/25	1094/216	163/22	421/61	164
12‐month OS (Chemotherapy/ PD‐1 combination)	0.49/0.69	0.57/0.67	0.45/0.53	0.53/0.44	0.56/0.62	0.51/0.56
Unadjusted Hazard ratio (HR) for death (95% CI)	0.49 (0.38–0.64)	0.99 (0.65–1.50)	0.79 (0.68–0.92)	1.10 (0.70–1.72)	0.92 (0.70–1.20)	0.97 (0.71–1.33)
Age HR (95% CI)
<65	0.43 (0.31–0.61)	1.25 (0.71–2.20)	0.75 (0.60–0.94)	1.30 (0.68–2.49)		1.26 (0.79–2.0)
>65	0.64 (0.43–0.95)	0.80 (0.42–1.53)	0.84 (0.69–1.03)	0.94 (0.49–1.81)	1.05 (0.88–1.26)	0.74 (0.48–1.15)
Sex HR (95% CI)
Male	0.70 (0.50–0.99)	0.81 (0.44–1.48)	0.75 (0.63–0.91)	1.08 (0.49–2.36)	0.96 (0.80–1.15)	1.31 (0.85–2.02)
Female	0.29 (0.19–0.44)	1.24 (0.70–2.22)	0.81 (0.63–1.03)	1.07 (0.62–1.87)		0.72 (0.45–1.14)
PD‐L1 expression status HR (95% CI)
<1%	0.59 (0.38–0.92)	1.84 (0.58–5.81)	1.02 (0.69–1.51)	1.17 (0.34–4.03)		NA
>1%	0.47 (0.34–0.66)	1.45 (0.57–3.67)	0.70 (0.55–0.90)	0.76 (0.33–1.74)	0.80 (0.56–1.14)	NA
1–49%	0.55 (0.34–0.90)	1.55 (0.56–4.30)	0.77 (0.57–1.05)	1.24 (0.44–3.45)	0.77 (0.52–1.13)	NA
>50%	0.42 (0.26–0.68)	0.91 (0.08–10.21)	0.69 (0.44–1.08)	0.31 (0.06–1.53)	0.70 (0.37–1.32)	NA
Brain metastases HR (95% CI)
Evidence of	0.36 (0.20–0.62)	1.63 (0.80–3.32)	0.96 (0.67–1.39)	0.95 (0.32–2.81)		1.44 (0.73–2.84)
No evidence of	0.53 (0.39–0.71)	0.78 (0.46–1.32)	0.76 (0.65–0.90)	1.12 (0.68–1.83)	1.04 (0.80–1.34)	0.86 (0.60–1.23)
Platinum‐based drug HR (95% CI)
Carboplatin	0.52 (0.39–0.71)	0.94 (0.62–1.44)	0.78 (0.67–0.90)	NA		0.94 (0.69–1.29)
Cisplatin	0.41 (0.24–0.69)	N/A	1.34 (0.19–9.71)	1.03 (0.66–1.63)	0.58 (0.38–0.88)	NA

CI, confidence interval; NA, not available; OS, overall survival; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1; rwOS, real‐world overall survival.